Healionics news

Healionics Corporation, a private medical device company, announced today the completion of a $4.7M equity financing round led by Keiretsu Capital. The company also announced the conversion to equity of $5.2M in previously outstanding notes and interest.

Healionics is preparing to commercialize its innovative STARgraft vascular graft, designed to provide a safer and more reliable means to access the bloodstream for dialysis in patients with kidney failure. An initial human study was c

Healionics Corporation, a private medical device company, announced today the completion of a $4.5M convertible note financing round.

The financing supports the first human study, currently underway, of the company`s innovative STARgraft vascular graft. In preclinical studies, STARgraft demonstrated improved ability to maintain blood flow compared to on-market vascular grafts, thereby offering the potential to reduce cost and morbidity while improving quality of life among dialysis

Healionics Corporation, a Seattle-based medical device company, has announced the addition of Ryan Takeuchi to its board of directors.
Takeuchi brings 20 years of experience in medical devices and private equity, and most recently served as divisional business leader of W.L. Gore’s Medical Products Division.

“We appreciate Ryan’s vote of confidence in Healionics and our market opportunity, particularly given his insight as recent head of the market leader in our

Healionics Corporation, a Seattle-based medical device company, has received notice from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of a $1.7M Fast-Track Small Business Innovation Research (SBIR) grant in support of regulatory approval and a clinical study of STARgraftTM, its innovative synthetic vascular graft. Andrew Marshall, Healionics’ Chief Technology Officer, is the Principal Investigator for the project.

Phase I of the grant ($440k) has

Healionics’ STARport HD, a novel preclinical stage implantable device that allows needle-free bloodstream access for hemodialysis treatment, has been selected by the American Society of Nephrology (ASN) to be featured at the ASN exhibit booth at Kidney Week 2016 as one of several new technologies portraying the future of kidney disease treatment.

Kidney Week 2016 is the 50th annual kidney research meeting for ASN. This year’s meeting, November 15-20 in Chicago, IL, is expe

Healionics Corporation, a Seattle-based medical device company, today announced the appointment of Mike Connolly as Chief Executive Officer. Connolly brings 25 years of leadership in the medical device industry including extensive experience in both operating and venture investing roles.

“We are fortunate to add a leader of Mike’s caliber,” said Andrew Marshall, Director and Chief Technical Officer of Healionics. “He brings a depth of relevant business experien

Healionics Corporation, a Seattle-based medical device company, was awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) to develop new vascular grafts for dialysis use that overcome the major problem of clotting failure. Andrew Marshall, Ph.D., Healionics’ Chief Technology Officer, is the Principal Investigator for the 3-Year project.

Healionics Corporation has been awarded a $150,000 Small Business Innovation Research (SBIR) contract from the Department of Defense (DOD) to demonstrate feasibility for an improved vascular graft design. Andrew Marshall, PhD, Healionics’ Chief Technology Officer, is the Principal Investigator for this research project.

Titled, “Biointegrated Synthetic Grafts for Vascular Reconstruction,” the contract provides sixmonth funding to show proof of concept for a new appro

Healionics Corporation has received a $224,500 Small Business Innovation Research (SBIR) grant award from the National Institute of Diabetes and Digestive and Kidney Diseases division of the National Institutes of Health (NIH) for preclinical studies to develop a novel vascular graft for use with needle-free hemodialysis access ports. Andrew Marshall, PhD, Healionics’ Chief Technology Officer, is the Principal Investigator for this research project.

Titled, “Vascular Graft

Healionics Corporation has received a further patent for its textured STAR Biointerface technology. The United States Patent and Trademark Office issued Patent No. 8,647,393, "Implantable Medical Devices Having Microporous Surface Layers and Method for Reducing Foreign Body Response to the Same.” This new patent extends the scope of 8,372,423 issued to Healionics in February 2013.

The STAR Biointerface is a textured porous tissue ingrowth layer that enhances the biocompatibility